OBJECTIVE To describe the prevalence of female sexual dysfunction in a well-defined polycystic ovary syndrome (PCOS) population, and to assess the impact of common PCOS treatments on sexual function. DESIGN Secondary analysis of a randomized controlled trial, oral contraceptive pills and weight loss in PCOS. SETTING Two academic medical centers. PATIENTS Women with PCOS (N = 114) defined by the Rotterdam criteria. INTERVENTIONS Continuous oral contraceptive pill (OCP) or intensive lifestyle modification (Lifestyle) or the combination (Combined) for 16 weeks. MAIN OUTCOME MEASURES Change in Female Sexual Function Index (FSFI) and Female Sexual Distress Scale-Revised (FSDS-R) scores after 16 weeks. RESULTS There was no change in total FSFI or FSDS-R score in any treatment group; however, an increase in the FSFI desire domain subscore was observed in the Lifestyle and Combined treatments, indicating improved sexual desire over the 16-week period. Overall, 33 participants (28.9%) met criteria for sexual dysfunction by FSFI criteria (baseline score ≤26.55). Among this group, FSFI score improved after 16 weeks of Lifestyle and Combined treatments. There was no change in prevalence of sexual dysfunction in treatment groups at 16 weeks. Use of OCPs did not alter FSFI scores. CONCLUSION(S) Female sexual dysfunction is highly prevalent among women with PCOS. Our findings suggest that common treatments for PCOS, including intensive lifestyle modification and the combination of intensive lifestyle modification and OCPs, have the potential to improve sexual function in these women; the mechanism for these improvements is likely multifactorial. CLINICAL TRIAL REGISTRATION NUMBER NCT00704912.

中文翻译：

---

单独或联合激素避孕药改变生活方式可改善多囊卵巢综合征女性的性功能障碍

目的 描述明确定义的多囊卵巢综合征 (PCOS) 人群中女性性功能障碍的患病率，并评估常见 PCOS 治疗对性功能的影响。设计 一项随机对照试验、口服避孕药和 PCOS 减肥的二次分析。地点 两个学术医疗中心。患者 患有 PCOS 的女性 (N = 114) 由鹿特丹标准定义。干预连续口服避孕药 (OCP) 或强化生活方式改变 (Lifestyle) 或联合用药 (Combined) 16 周。主要结果测量 16 周后女性性功能指数 (FSFI) 和女性性困扰量表修订版 (FSDS-R) 评分的变化。结果 任何治疗组的总 FSFI 或 FSDS-R 评分均无变化；然而，在生活方式和联合治疗中观察到 FSFI 欲望领域分值增加，表明在 16 周期间性欲得到改善。总体而言，33 名参与者 (28.9%) 符合 FSFI 标准的性功能障碍标准（基线评分≤26.55）。在该组中，FSFI 评分在 16 周的生活方式和联合治疗后有所改善。在 16 周时，治疗组的性功能障碍患病率没有变化。使用 OCP 不会改变 FSFI 分数。结论 女性性功能障碍在 PCOS 女性中非常普遍。我们的研究结果表明，PCOS 的常见治疗方法，包括强化生活方式改变以及强化生活方式改变和 OCP 的结合，有可能改善这些女性的性功能；这些改进的机制可能是多因素的。临床试验注册号 NCT00704912。